New Glu Research Opportunity
We’re partnering with our friends at Tidepool to study how daily highs and lows might affect the health and well-being of people with type 1 diabetes.
Articles > Insulins & Non-insulins
Sanofi has asked the FDA to approve the dual SGLT1 and SGLT2 inhibitor as a possible add-on to insulin therapy. By Craig Idlebrook/GluCraig Update: On May 22, 2018, the FDA has accepted Sanofi’s filing for sotagliflozin, which would be marketed as Zynquista. For more information, click here. You can read more about the oral drug below. The FDA […]
Has there ever been a food more beloved and yet more challenging for people with type 1 diabetes? Something about that high carb/high fat mix makes pizza both incredibly delicious and incredibly difficult to control blood sugar! Here at Glu, GluAlex attempted to find the right pizza bolus. Here’s what he learned: Project Pizza Night […]
Researchers found that higher stress levels were associated with higher post-meal blood glucose levels for people with type 1 diabetes. -Danielle Gianferante/GluDanielle According to a recent study, stress can affect blood glucose levels — but only after eating. For the University Hospital of Zurich study, forty participants (21 men, 19 women) with type 1 diabetes came […]
The FDA recently mandated that users of SGLT-2 inhibitor drugs be warned of the risks of diabetic ketoacidosis (DKA) after receiving more than 70 reports of DKA. The agency previously issued a safety statement regarding these drugs’ potential dangerous side effects. SGLT-2 inhibitors, such as empagliflozin (Jardiance), dapagliflozin (Farxiga), and canagliflozin (Invokana), are a promising […]